Key result
Intravenous terbutaline significantly increased right ventricular ejection fraction at rest from 45% to 53% (P<0.01) in patients with severe chronic pulmonary disease.
Why the study?
Does intravenous terbutaline improve right ventricular function and pulmonary haemodynamics in patients with severe chronic pulmonary disease?
Does intravenous terbutaline improve right ventricular function and pulmonary haemodynamics in patients with severe chronic pulmonary disease?
Absolute Event Rate: 53% vs 45%
p-value: p=<0.01
Intravenous terbutaline acutely augments right ventricular function and decreases pulmonary vascular resistance in patients with severe chronic pulmonary disease.
No takes yet. Share an insight, caveat, or question.
May support acute RV augmentation with terbutaline; hypothesis-generating and should not change practice without controlled trials.
Eliasen et al. (1991) studied severe chronic pulmonary disease (n=20). Intravenous terbutaline vs. Baseline (pre-infusion) was evaluated on Right ventricular ejection fraction at rest (p=<0.01). Intravenous terbutaline significantly increased right ventricular ejection fraction at rest from 45% to 53% (P<0.01) in patients with severe chronic pulmonary disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: